摘要
目的探讨乳腺病变患者C-erbB-2的基因产物P185蛋白血清水平测定在临床中的应用价值。方法酶联免疫吸附试验(ELISA)检测42例乳腺癌、29例乳腺良性病变及40例体检者血清中P185蛋白的含量。结果乳腺癌和乳腺良性病变患者血清P185蛋白的平均水平分别是(22.67±12.61)、(8.34±5.70)mg/L,两者之间具有显著性差异(P<0.05);与正常体检者(5.79±4.47)mg/L相比,乳腺癌患者血清P185蛋白水平明显增高,具有统计学差异(P<0.05)。以cut-off值为15.8 mg/L判断,乳腺癌组血清P185蛋白的阳性率为45.2%。结论用ELISA法检测血清中C-erbB-2基因产物P185蛋白水平,有助于术前对乳腺病变的辅助诊断。
Objective To study the extracellular level of P185, a soluble oncoprotein fragment of C - erbB - 2, in breast cancer patients. Methods Serum samples from 42 patients with primary breast cancer, 29 with benign breast diseases and 40 healthy controls, were assayed in an ELISA for P185. Results The serum level of P185 was higher in the cancer patients than in the patients with benign breast diseases and healthy controls [ （22.67±12.61 ） mg/L vs. （ 8.34±5.70） mg/L and （ 5.79 ± 4.47） mg/L respectively, P 〈 0.05 ]. Let 15.8 mg/L be the cut - off value, the positive rate of P185 for breast cancer patients will be 45.2%. Conclusion Monitoring of serum C - erbB - 2 level helps to appreciate the status of breast cancer before it is treated.
出处
《徐州医学院学报》
CAS
2008年第6期371-373,共3页
Acta Academiae Medicinae Xuzhou
基金
徐州市科技局资助项目(X2004425-2)
